Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of cancer that develops from a specific white blood cell called B cells or B lymphocytes. Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell cancers su

Trial Details

NCT ID
NCT05943496
Phase
PHASE1
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Acalabrutinib
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Echocardiography
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific …
  • Age \>= 18 years. All genders, races, and ethnic groups will be included
  • Ability to swallow and retain oral medication
  • Documented previously untreated CLL/SLL. Diagnosis must be confirmed by peripheral blood flow cytometry or lymph node biopsy and made in accordance…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →